With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks to buy according to hedge funds. Meanwhile, analysts see 9.20% upside for the stock. That outlook comes during a particularly active stretch of regulatory and clinical news for Lilly’s drug pipeline.
On June 9, 2026, the FDA approved a new maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing a single 250 mg injection every eight weeks for adults and children 12 and older weighing at least 88 pounds with moderate-to-severe atopic dermatitis. EBGLYSS was already approved for once-monthly maintenance dosing, and the new option gives patients as few as six maintenance injections per year.
That update followed a wave of diabetes and obesity data presented at the ADA 86th Scientific Sessions.
On June 8, 2026, Eli Lilly and Company (NYSE:LLY) reported that Foundayo (orforglipron) outperformed oral semaglutide on A1C reduction and weight loss in the ACHIEVE-3 trial, with similar gains shown in ACHIEVE-2 and ACHIEVE-5. A day earlier, Lilly said Foundayo produced significant weight loss across all stages of menopause in post-hoc analyses of the ATTAIN-1 and ATTAIN-2 trials. Additionally, on June 6, 2026, Eli Lilly and Company (NYSE:LLY) reported full data from retatrutide’s TRIUMPH-1 obesity study and TRANSCEND-T2D-1 study in type 2 diabetes, showing substantial weight loss alongside improvements in knee osteoarthritis pain, sleep apnea, and A1C levels.
Following those updates, Jefferies raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330 and kept a “Buy” rating. The firm said some safety observations were manageable and that retatrutide’s overall profile would be difficult to beat in a modern large-scale global obesity Phase 3 trial.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products across cardiometabolic health, oncology, and immunology.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.